

Prolonged nightly fasting for multiple myeloma prevention (PROFAST): design and rationale of a randomized controlled pilot trial

David J. Lee, Elizabeth K. O'Donnell, Noopur Raje, Cristina Panaroni, Robert Redd, Jennifer Ligibel, Dorothy D. Sears, Omar Nadeem, Irene M. Ghobrial, Catherine R. Marinac

Submitted to: JMIR Research Protocols
on: July 31, 2023

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript.....	5
---------------------------------	----------

Preprint
JMIR Publications

Prolonged nightly fasting for multiple myeloma prevention (PROFAST): design and rationale of a randomized controlled pilot trial

David J. Lee^{1, 2, 3} MD, MPH, MMSc; Elizabeth K. O'Donnell^{3, 4} MD; Noopur Raje^{1, 3} MD; Cristina Panaroni^{1, 3} PhD; Robert Redd² MS; Jennifer Ligibel^{2, 3} MD; Dorothy D. Sears⁵ PhD; Omar Nadeem^{3, 4} MD; Irene M. Ghobrial^{3, 4} MD; Catherine R. Marinac^{3, 4} PhD

¹Massachusetts General Hospital Boston US

²Dana-Farber Cancer Institute Boston US

³Harvard Medical School Boston US

⁴The Center for Prevention of Progression of Blood Cancer Dana-Farber Cancer Institute Boston US

⁵College of Health Solutions Arizona State University Phoenix US

Corresponding Author:

David J. Lee MD, MPH, MMSc
Massachusetts General Hospital
55 Fruit St.
Bigelow 740
Boston
US

Abstract

Background: Obesity is an established, modifiable risk factor of multiple myeloma (MM), yet no lifestyle interventions are routinely recommended for overweight and obese patients with MM precursor conditions. Prolonged nightly fasting is a simple, practical dietary regimen, supported by research suggesting that the synchronization of feeding-fasting timing with sleep-wake cycles favorably affects metabolic pathways implicated in the development of MM. We describe the design and rationale of a randomized controlled pilot trial evaluating the efficacy of a regular, prolonged nighttime fasting schedule among overweight and obese individuals at high risk for developing MM or a related lymphoid malignancy.

Objective: The PROFAST Study is a randomized controlled pilot trial investigating the effects of a 4-month prolonged nightly fasting regimen on body composition and tumor biomarkers among overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or smoldering Waldenström macroglobulinemia (SWM).

Methods: Individuals with MGUS, SMM, or SWM aged >18 years and a body mass index of 25 kg/m² or above are randomized to either a 14-hour nighttime fasting intervention (n=20) or a healthy lifestyle education control group (n=20). Participants receiving the fasting intervention are supported through one-on-one telephone counseling by a health coach as well as automated text messaging to support fasting goals. Primary endpoints of body composition (by Dual-Energy X-ray Absorptiometry scan), bone marrow adiposity (by bone marrow histology), and tumor biomarkers (M-protein and light chain concentrations by gel-based and serum free light chain assays) are assessed at baseline and at the end of the 4-month study period.

Results: Participant recruitment commenced in April 2023 and is expected to be completed by April 2024.

Conclusions: This study will serve as an important first step in exploring the premise that prolonged nightly fasting is a strategy to control obesity and prevent and intercept disease progression in individuals with MM precursor conditions. Findings from this pilot study may inform clinical and public health strategies for MM prevention. Clinical Trial: ClinicalTrials.gov NCT05565638

(JMIR Preprints 31/07/2023:51368)

DOI: <https://doi.org/10.2196/preprints.51368>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.
Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org/preprint/51368>, my manuscript will be published in JMIR Publications.



Original Manuscript

**Prolonged nightly fasting for multiple myeloma prevention (PROFAST):
design and rationale of a randomized controlled pilot trial**

David J. Lee, MD, MPH, MMSc^{1,2,3*^}

Elizabeth K. O'Donnell, MD^{2,3,4}

Noopur Raje, MD^{1,2}

Cristina Panaroni, PhD^{1,2}

Robert Redd, MS⁵

Jennifer Ligibel, MD^{2,3}

Dorothy D. Sears, PhD⁶

Omar Nadeem, MD^{2,3,4}

Irene M. Ghobrial, MD^{2,3,4}

Catherine R. Marinac, PhD^{2,3,4}

¹Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

²Harvard Medical School, Boston, MA, USA

³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

⁴The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA

⁵Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

⁶College of Health Solutions, Arizona State University, Phoenix, AZ, USA

[^]Corresponding author:

David J. Lee, MD, MPH, MMSc

Massachusetts General Hospital

55 Fruit Street, Bigelow 740, Boston, MA 02114

Phone: 617-643-0596 | Email: DJLee@mgh.harvard.edu

Keywords: MGUS, Smoldering myeloma, cancer prevention, intermittent fasting

Word Count (Limit 4,000): 3920

Abstract (Limit: 450): 445

Funding

This study was funded in part by the National Institutes of Health (R25AI147393, R38HL150212, R21 CA256644, K22 CA251648, R25 AI147393, R38 HL150212) and the Paula and Roger Riney Foundation.

ABSTRACT

Background: Obesity is an established, modifiable risk factor of multiple myeloma (MM), yet no lifestyle interventions are routinely recommended for overweight and obese patients with MM precursor conditions. Prolonged nightly fasting is a simple, practical dietary regimen, supported by research suggesting that the synchronization of feeding-fasting timing with sleep-wake cycles favorably affects metabolic pathways implicated in the development of MM. We describe the design and rationale of a randomized controlled pilot trial evaluating the efficacy of a regular, prolonged nighttime fasting schedule among overweight and obese individuals at high risk for developing MM or a related lymphoid malignancy.

Objective: The PROFAST Study (NCT05565638) is a randomized controlled pilot trial investigating the effects of a 4-month prolonged nightly fasting regimen on body composition and tumor biomarkers among overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or smoldering Waldenström macroglobulinemia (SWM).

Methods: Individuals with MGUS, SMM, or SWM aged ≥ 18 years and a body mass index of 25 kg/m² or above are randomized to either a 14-hour nighttime fasting intervention (n=20) or a healthy lifestyle education control group (n=20). Participants' baseline diet and lifestyle patterns are characterized through two 24-hour dietary recalls; questionnaires querying demographic, comorbidity, lifestyle, and quality-of-life information; and wearing of an ActiGraph on the wrist for 7 days. Participants randomized to the fasting intervention are supported through one-on-one telephone counseling by a health coach as well as automated text messaging to support fasting goals. Primary endpoints of body composition, including visceral and subcutaneous fat (by Dual-Energy X-ray Absorptiometry scan); bone marrow adiposity (by bone marrow histology); and tumor biomarkers, specifically M-proteins and serum free light chain concentrations (by gel-based and serum free light chain assays) are assessed at baseline and at the end of the 4-month study period.

Changes in these endpoints are evaluated from baseline to follow-up in the two groups using a repeated measures mixed-effects model that accounts for the correlation between baseline and follow-up measures and is generally robust to missing data. Feasibility is assessed as participant retention (percent dropout in each arm) and percentage of days participants achieved a ≥ 14 -hour fast.

Results: Participant recruitment commenced in April 2023 and is expected to be completed by April 2024.

Conclusions: PROFAST serves as an important first step in exploring the premise that prolonged nightly fasting is a strategy to control obesity and obesity-related mechanisms of myelomagenesis. In evaluating the feasibility and impact of prolonged nightly fasting on body composition, bone marrow adipose tissue, and biomarkers of tumor burden, this pilot study may generate hypotheses regarding metabolic mechanisms underlying MM development and ultimately inform clinical and public health strategies for MM prevention.

Trial Registration: ClinicalTrials.gov NCT05565638

INTRODUCTION

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is preceded by well-defined precursor conditions, called monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) [1,2]. MGUS and SMM are asymptomatic conditions that have an annual progression rate to overt MM of 1% and 10% per year, respectively, but can be as high as 58% in 20 years in certain risk groups [3,4]. Despite the increasingly strong interest in intervening at the precursor stage for the early interception and prevention of MM, safe and cost-effective interventions are lacking. While clinical trials have shown that earlier initiation of anti-MM therapies at the precursor stage (e.g., lenalidomide-based regimen for high-risk SMM [5]) may alter the natural disease course and improve survival [5,6], early treatment remains highly controversial due to high costs and toxicity risks to patients, limiting its use to only a subset of patients at the highest risk strata [7–10].

Lifestyle interventions targeting excess adiposity and metabolic health in precursor patients may have an important role in MM prevention. Obesity is a well-established, potentially modifiable risk factor of MM [11], and there is accumulating evidence that obesity may also increase the risk of MGUS and its progression to overt MM [12–14]. While current dietary and weight control guidelines for cancer prevention focus largely on calorie restriction and optimizing intake of specific food groups [15], challenges related to their integration into individuals' daily lives for a sustained period of time remain a consideration [16–19]. Time-restricted feeding, a form of intermittent fasting whereby *ad libitum* energy consumption is constrained to a window of time (typically between 4 and 12 hours daily), may be a simple, feasible alternative for weight loss and cancer risk reduction [16,20]. When food intake timing occurs during the wake phase of the 24-hour day, time-restricted feeding may benefit metabolic health and cancer risk by synchronizing feeding-fasting regimens with daily circadian rhythms, which, in turn, improve oscillations in the circadian clock expression of numerous genes important for glucose metabolism and overall cellular homeostasis (e.g., autophagy, DNA damage repair) [16,21,22].

The PROFAST Study (NCT05565638) is a randomized controlled pilot trial investigating the clinical benefit of a 4-month prolonged nightly fasting regimen in overweight and obese individuals with MGUS, SMM, and smoldering Waldenström macroglobulinemia (SWM). The intervention is supported by evidence that prolonged nighttime fasting is not only a simple and sustainable behavior change [16,23], but also improves metabolism and body weight regulation [24–29]. Here, we describe the study design, rationale, and framework for assessing the potential clinical significance of a low-risk, cost effective lifestyle intervention in patients with multiple myeloma precursor conditions.

METHODS

Design of PROFAST

PROFAST is a pilot randomized controlled trial of our 4-month PROlonged nightly FASTing intervention in overweight and obese patients with MGUS, SMM, or SWM. The goal of the trial is to acquire preliminary outcome data for the efficacy of a prolonged nightly fasting on body composition and clinical markers of disease progression in precursor patients. Participants are randomly assigned to (1) a theory-based intervention designed to promote a 14-hour fast during the nighttime hours or (2) the healthy lifestyle education control group. All study procedures and materials have been approved by the Institutional Review Board at the Dana-Farber Cancer Institute (DFCI).

Participants and Eligibility

Eligible participants are at least 18 years of age, have a BMI of ≥ 25 kg/m², and have a documented diagnosis of MGUS, SMM or SWM via review of their electronic medical records. As shown in Table 1, inclusion criteria include: (1) currently fasting for <14 hours per night as assessed via self-report and using 24-hour food recalls and (2) own a cell phone and are comfortable sending and receiving text messages. Exclusion criteria are having: (1) overt MM; (2) other cancer(s) requiring active therapy; (3) diabetes mellitus, which may increase risk of hypoglycemia with a prolonged fast, unless with physician who manages their clinical care provides consent that they may enroll; or (4) any other condition or circumstance, which in the investigators' judgement, would be a contraindication to nightly fasting and/or interfere with trial participation (e.g., night shift work, night eating syndrome, taking weight loss medication, participation in another weight loss program). Participants are primarily recruited from the DFCI Center for Early Detection and Interception of Blood Cancers, a clinic focused on evaluating patients diagnosed with precursor conditions of hematologic malignancies and works with patients to manage their risk of disease progression.

Clinic Visits and Randomization

Upon completion of the consent form, participants attend a baseline clinic visit which includes laboratory, self-report, and physical assessments, as shown in Figure 1. In particular, participants

have their height and weight measured and receive a Dual-Energy X-ray Absorptiometry (DXA) scan to evaluate body composition. Participants provide biospecimen samples (i.e., blood, bone marrow aspirate/biopsy). For each blood draw, approximately 30-60 mL of blood per participant are collected into EDTA and SST tubes for immediate plasma and serum preparation, respectively, and aliquots of plasma and serum in 1.8 mL cryovials are placed in an -80°C freezer for storage. As for bone marrow samples, approximately 20 mL of bone marrow are collected into EDTA tubes for immediate processing, and the processed samples are placed in cryovials in a slow freeze cryostorage for 1-7 days before moving to storage in liquid nitrogen tank.

Participants' current diet and lifestyle patterns are characterized through two 24-hour dietary recalls; questionnaires ascertaining demographic, comorbidity, lifestyle, and quality-of-life information; and the wearing of an ActiGraph accelerometer on their wrists for 7 days for baseline assessment of sleep, physical activity, and circadian rhythm.

Within 28 days of completing baseline assessments, participants are randomized in a 1:1 manner to either the nighttime 14-hour fast intervention group or the healthy lifestyle education comparison group. Once randomized, participants initiate the intervention/control condition ideally no later than 28 days of baseline screening assessments.

A clinic visit is scheduled 4 months after initiating and ideally within 7 days of completing the intervention/control condition. At this final visit, participants' weight, biospecimens and clinical labs, DXA scan, and self-reported outcome measures are reobtained.

Details of Intervention

The intervention goal is to achieve a 14-hour nightly fast. Fasting goals during the initial weeks of the study are individualized, allowing participants to gradually adopt a 14-hour fasting duration on or before the third week of study. A 14-hour window was selected because it has been demonstrated to be an achievable intervention target in other populations of adults with chronic health conditions and

studies to date suggest it is a sustainable intervention target [29,30]. Specifically, previous interventions have reported elective continuation of the intervention beyond the intervention period, resulting in sustained health benefits including weight loss [29,30]. The overnight fasting period is defined as the longest interval of time overnight in which no calorie-containing foods or beverages are consumed. Given prior findings that fasting may be more beneficial when aligned with the biological night [26], participants are encouraged to begin their nightly fast by 8 pm. To maximize acceptability and adherence to the intervention protocol, participants are allowed to consume non-caloric beverages including water, plain coffee, plain tea, zero-calorie sodas, and calorie-free sweeteners.

The intervention delivery consists of one-on-one telephone counseling by a health coach and a text messaging system to support this target. Participants are supported through telephone counseling during the initial phase (weeks 1-3) of the interventional period and gradually transition to activities that promote self-reliance for behavioral maintenance beginning week 4 until the end of study. The intervention incorporates a number of theory-based behavior change strategies in its design [31–33], including those grounded in social cognitive theory and its central tenet of self-efficacy [31].

Text Messaging System

A text messaging system was developed in collaboration with Mosio, Inc. (San Francisco, CA) and is introduced to participants during week 3 of the study for the purpose of self-monitoring, tracking adherence, and encouraging maintenance of prolonged nightly fasting. Participants are asked to text the study team to indicate when they began and ended their overnight fast. Participants receive an automatic response to their messages with positive reinforcement if the fasting goal was successfully achieved or corrective tools, such as a behavioral strategy, that may help them achieve a longer fast. The messages sent back to participants also contain feedback about their cumulative adherence to the prolonged overnight fasting pattern, calculated as the percentage of the successful overnight fasts during the past week. Participants also receive a text message each day

to remind them of their target end time of the overnight fast as well as encouraging text messages to promote adherence that are customized to past performance. An example of text messages sent to and received from participants through the automated text messaging system is provided in Figure 2.

Healthy Lifestyle Education Control

Participants in the control arm receive educational information regarding healthy lifestyle to enhance retention of participants randomized to this group. At baseline, control participants receive an educational session with the health coach and a workbook containing brief information about topics about a healthy lifestyle (e.g., sun safety, sleep, hydration, sitting less). It is notable that research indicates that a single education session has only modest and temporary impacts on behaviors among most individuals [34,35]. To support sustained engagement throughout the 4-month study period, control group participants also receive one email and one text message per week by the same text messaging system used for participants in the interventional arm. These text messages contain a mixture of educational information and potential personalized touch points to help participants feel valued.

Primary Endpoints

A challenge in assessing the clinical benefit of short-term interventions in MGUS, SMM, and SWM is that precursor patients are expected to have a relatively small number of progression events over months to years, limiting the ability to evaluate these events as the outcome. In the current study, we focus on body composition, bone marrow adipose tissue, and biomarkers of tumor burden, which are accessible outcome measures in evaluating the efficacy of our lifestyle-intervention.

Body Composition and Bone Marrow Adiposity

Most investigations evaluating the association of obesity and MGUS and MM have utilized BMI as a surrogate measure of obesity [12,13,36,37], and while BMI is a convenient, inexpensive measurement [38], it has low specificity for identifying excess adipose tissue and does not account for the type and distribution of fat (visceral and subcutaneous fat) [39,40]. These shortcomings of BMI limit our understanding of the relationship between obesity and the development of MM, as different adipose tissue compartments are known to have differential influences on obesity-related diseases [41–43]. For example, visceral fat is a metabolically active tissue type that releases fatty acids and pro-inflammatory substances and, in comparison to subcutaneous tissue, is more strongly associated with components of metabolic syndrome [41–43]. Thus, in our study, DXA scan (Horizon W DXA; Hologic, Inc.) is used to measure body composition, differentiating not only fat mass from lean mass but also among adipose tissue types (visceral and subcutaneous fat). Furthermore, bone marrow adipose tissue is an understudied adipose depot with endocrine and paracrine signaling functions linked with the proliferation of nearby MM cells [44]. In our study, total marrow lipid content is quantified in bone marrow aspirate samples. Adipocyte/lipid content is analyzed using histology, flow cytometry, and lipidomics on adipocyte-enriched fractions. By measuring and comparing these adiposity measures between baseline and end-of-study, our study is able to evaluate whether prolonged nightly fasting possibly improves the body composition profile of participants.

Clinically Available Tumor Biomarkers

Serum protein electrophoresis supplemented by immunofixation (SPEP/IFX) and serum free light chains (SFLCs) are the most commonly utilized clinical tests used to monitor patients at all stages of the disease continuum (MGUS, SMM, and MM). Monoclonal immunoglobulin (M-protein) and light chain concentrations, as measured by SPEP/IFX and SFLCs correlate with overall tumor burden and importantly decrease after treatment with a range of mild and aggressive MM therapies [45–47]. These biomarkers are sensitive and measurable variables of tumor response to treatment [48] and, therefore, serve as clinically relevant disease endpoints for our lifestyle-related intervention pilot study.

Other Endpoints

Metabolomics

Metabolomics—the high-throughput identification and quantification of small molecule metabolites—is the study of metabolic changes in biological systems and provides the small molecule fingerprints that reflect the complex relationships between diet, lifestyle (obesity), genes, and disease processes [49]. Metabolomics can yield novel insights into pathogenesis and risk of cancer and chronic disease [49,50]. Particularly important categories of metabolites in cancer and metabolic disease are metabolites of glycolysis and the TCA cycle [51,52]. These are of interest to the current study because of their critical role in tumor growth and because they have been shown to be obesity-related [53]. Metabolomics-based data of MGUS, SMM, and MM are limited to only a small number of studies, including one by Ludwig et al. that identified 25 bone marrow metabolites that differed between 10 MGUS and 10 MM patients [54–59]. Of all molecular entities in the body (e.g., genes, transcripts, proteins, metabolites), metabolites as the final products of biochemical processing have the closest relationship to expressed phenotype [60]. Thus, we believe that metabolomics offers a unique lens to study progression of MM precursors..

Quality of Life

Given the high rates of anxiety and distress document in individuals with MGUS and SMM and lack of evidence-based risk reduction strategies available for preventing disease progression to MM [61,62], we evaluate the psychosocial benefits of offering a low-risk lifestyle intervention to this patient population, as an exploratory objective. Quality of life is assessed using the well-validated PROMIS global health survey [63–65]. Cancer worry is assessed utilizing a 4-item scale adapted from Lehrman and colleagues [63–65].

Baseline Dietary and Lifestyle Assessment

Participants undergo two 24-hour dietary recalls to assess food beverage consumption (ideally for 1

weekday and 1 weekend day), which are conducted through the Behavioral Measurement and Interventions Shared Resource (BMISR) at the University of Arizona Cancer Center. Participants also complete a baseline survey querying sociodemographic variables (age, sex, race, ethnicity, highest level of education attained, and annual family income), medical comorbidities (e.g., hypertension, hyperlipidemia, diabetes mellitus), and lifestyle factors (e.g., smoking, physical activity, sleep impairment and disturbance) measured by well-validated instruments [66–71]. Finally, participants are asked to wear an ActiGraph accelerometer (GT3XP-BTLE; ActiGraph Corp., Pensacola, FL) on their wrists for 7 days for a baseline assessment of physical activity, sleep, and circadian rhythm parameters [72–74].

Feasibility, Acceptability, Fidelity, and Safety

Feasibility is assessed as participant retention (percent dropout in each arm) and percentage of days participants achieved a ≥ 14 -hour fast. Acceptability is assessed as perceived effectiveness of intervention components, plans to continue to engage in a prolonged nightly fast, elements of intervention liked/disliked, and satisfaction with program delivery and staff. Items are rated on a scale from 1 to 5. Finally, fidelity is assessed as percentage of days participants recorded fasting duration via the SMS system, percentage of SMS messages read, and percentage of calls with health coach.

Safety is monitored and assessed by the number and severity of adverse events, according to the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Individuals with any medical or lifestyle condition (e.g., diabetes mellitus) that are deemed to elevate their risk of adverse events from the intervention are excluded from the study (Table 1). Participants are informed of expected side effects related to fasting (e.g., lightheadedness, headaches, restlessness, irritability, and low blood glucose), and adverse events that vary in nature, intensity, and frequency

from what is expected are reported.

Analysis

Plan

The key outcomes evaluating in this trial are changes in body composition (with a focus on visceral and subcutaneous adiposity), M-protein concentrations, and bone marrow adiposity. Changes in these endpoints are evaluated from baseline to follow-up in the two groups using a repeated measures mixed-effects model that accounts for the correlation between baseline and follow-up measures and is generally robust to missing data. The baseline values of the dependent variables (e.g., weight, M-protein level) and disease subtype are included as covariates in the regression models. Group-by-time interaction terms are included as fixed-effects in the regression model. Model fit is assessed using standard methods.

RESULTS

Participant recruitment commenced in April 2023 and are expected to be completed by April 2024.

DISCUSSION

The PROFAST Study provides important preliminary data regarding the impact of prolonged nightly fasting on body composition, bone marrow adipose tissue, and biomarkers of tumor burden (SPEP/IFX and SFLCs) in patients with MM precursor conditions, thereby generating hypotheses on how targeting obesity-related mechanisms of carcinogenesis may help prevent MM development.

Obesity is a well-established, potentially modifiable risk factor of MM [11], and there is accumulating evidence that obesity may also increase the risk of MGUS and its progression to overt MM [12–14]. A study of three large prospective cohorts of U.S.-based adults followed over 5 million person-years observed a 17% increase in MM risk per 5 kg/m² increase in body mass index (BMI) [36]. Another study of 7,818 MGUS patients in the U.S. Veterans Health Administration database, being overweight and obesity were associated with an increased risk of transformation to MM (HR for overweight: 1.55; 95% CI: 1.16, 2.06) (HR for obesity: 1.98; 95% CI: 1.47, 2.68) [12]. Concordant with these findings, a more recent analysis of MGUS patients identified through a population-based screening study in Olmstead County, Minnesota, between 1995 and 2003 observed that having a BMI ≥ 25 was also associated with increased progression to MM or other plasma cell or lymphoid disorder in univariate analysis (HR, 2.14; 95% CI, 1.05-4.36) as well as in a multivariable model accounting for clinical factors [13].

These epidemiological studies are supported by mechanistic evidence that obesity may lead to chronic low-grade inflammation and dysregulation of endogenous growth factors linked to myelomagenesis [75,76], together suggesting that weight control may be an effective MM prevention strategy. Indeed, according to a compelling 2016 consensus statement, an expert panel convened by the International Agency for Research on Cancer concluded there is sufficient

mechanistic evidence that a preventative relationship has been established between the “absence of body fatness” and MM [75]. In obesity, adipose tissue, including adipocytes in the bone marrow, is altered in ways that may promote carcinogenesis, including by creating an unfavorable tumor microenvironment in which MM can engraft and grow [44,77]. Notably, the adipose tissue of obese individuals leads to excess free fatty acids as well as altered levels of proinflammatory cytokines (e.g., TNF- α , IL-6), adipokines (e.g., adiponectin, leptin), and metabolic peptide hormones (e.g., insulin, IGF-1) [44,77,78]. Dysregulated levels of these biological compounds may fuel tumor initiation and influence the genetic characteristics of MM cells in ways that increase cell proliferation [79], reduce apoptosis [80], and contribute to immune cell evasion [81,82]. The implication of these factors is that weight loss may curb the contribution that excess adiposity-associated chronic inflammation and metabolic dysregulation have on MM development.

Beyond weight loss, the PROFAST Study tests the hypothesis that when we eat, not just what or how much we eat, is relevant to cancer prevention [24,25,83,84]. There is evidence suggesting that chronic exposure to circadian rhythm disturbances may lead to metabolic dysregulation, upregulation of proinflammatory cytokines, and abnormal cell proliferation [21,85]. As food intake contributes to the setting of circadian clock rhythms in peripheral organs, such as by inducing changes in body temperature and through the action of hormones like insulin and nutrient-sensing enzymatic and nuclear receptor signaling systems [21,86], the synchronization of feeding-fasting patterns with circadian rhythms may be important for preventing chronic diseases [24,26,27]. This hypothesis is supported by a large prospective study of early-stage breast cancer patients, which observed that short nightly fasting duration (<13 hours per night), compared to nightly fasting of ≥ 13 hours, was associated with an increased risk of breast cancer recurrence [25]. In that same study, each 2-hour increase in the nightly fasting duration was associated with lower hemoglobin A_{1c} levels and longer duration of nighttime sleep [25]. These findings are consistent with the results of population-based studies [24,26,27], including a large case-control study in Spain which observed that diurnal eating patterns, specifically in maintaining longer time intervals between the last meal of

the day and initiation of sleep, was inversely associated with risk of breast and prostate cancer [27]. Similarly, two U.S.-based studies of 2009-2010 National Health and Nutrition Examination Survey (NHANES) data evaluating biomarkers of breast cancer risk observed that longer duration of nighttime fasting was associated with improved measures of glycemic control and systemic inflammation [24,26], aligning with pathophysiological mechanisms underlying cancer risk [75].

Results from these human observational studies are consistent with rodent studies demonstrating that mice subjected to a time-restricted (16-hour) fasting regimen of a high-fat diet during the sleep phase were protected against weight gain, abnormal glucose metabolism, and inflammation, all of which were associated with cancer outcomes [22,87–90]. Notably, protective effects were observed despite these mice having the same caloric intake as those that had *ad libitum* access to food and ate frequently throughout day and night [22], suggesting that the beneficial effects of this fasting regimen was partly mediated through mechanisms independent of calorie restriction. Together, these data provide a strong basis of our intervention aimed to curb the inflammatory and metabolic mechanisms shown to contribute to myelomagenesis [44,76].

Finally and importantly, prolonged nightly fasting represents a lifestyle modification that is safe, practical, and acceptable for patients who otherwise are managed by a “watchful waiting” strategy. Patients with MM precursor conditions are reported to have diminished quality of life, increased comorbidities, and heightened anxiety and a sense of loss of control regarding their MM risk [61,62,91,92]. There is, therefore, a need to identify lifestyle-based interventions that patients can safely and practically adopt into their daily lifestyles and ultimately help curb disease progression. Fasting, as a practice, developed independently among different people groups and religions (e.g., Ramadan in Islam) around the world [93], and intermittent fasting has become one of the most common dietary patterns reported in the U.S. [94]. Prolonged nightly fasting is attractive due to its simplicity and feasibility, as supported by evidence from clinical trials of time-restricted eating strategies [16,23], and, thus, may be a potentially effective disease prevention strategy at the

population level [16].

Limitations of this study include the relatively small sample size of the study and the potential lack of sociodemographic and geographic diversity of participants due to recruitment occurring at a single academic institution, thus, possibly impacting generalizability of findings. Also, participants willing to participate in a 4-month prolonged overnight fasting intervention may not be representative of the general population of overweight or obese patients with MM precursors, and selection bias for patients who are motivated to participate in PROFAST could increase the study adherence rate. Furthermore, while participants in the intervention group are prescribed solely a prolonged overnight fasting regimen with no other recommendations regarding lifestyle patterns, it is theoretically possible that participants may change their dietary, physical activity, and sleep habits, due to paying closer attention to the timing of their eating and evaluations of their body composition pre- and post-intervention. These changes may also impact outcomes.

In summary, the study described herein serves as an important first step in exploring the premise that prolonged nightly fasting is a practical, effective strategy to control obesity and intercept disease progression in individuals with MM precursor conditions. By evaluating the impact of this lifestyle intervention on relevant biomarkers of excess adiposity and myeloma tumor burden, this pilot study may generate hypotheses and inform further investigations in identifying clinical and public health strategies for MM prevention.

Data Availability

Data sharing is not applicable to this article as no data sets were generated or analyzed during this study.

Conflicts of Interest

Dr. Ghobrial has served as a consultant for AbbVie, Adaptive, Aptitude Health, BMS, Cellectar, CurioScience, Genetch, Janssen, Janssen Central American and Caribbean, Karyopharm, Medscape, Oncopeptides, Sanofi, Takeda, The Binding Site, Gene Network Sciences Healthcare, and GSK. Dr Ghobrial's spouse, William Savage, is CMO and equity holder at Disc Medicine.

REFERENCES

1. SEER Cancer Statistics Review, 1975-2013 [Internet]. Bethesda, MD: National Cancer Institute; 2016 Apr [cited 2023 Jun 8]. (Howlander N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al., editors. based on November 2015 SEER data submission, posted to the SEER web site, April 2016). Available from: https://seer.cancer.gov/archive/csr/1975_2013/
2. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2006 Mar 30;354(13):1362–9.
3. Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. *Hematol Am Soc Hematol Educ Program*. 2013;2013:478–87.
4. Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*. 2010 Jun;24(6):1121–7.
5. Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. *N Engl J Med*. 2013 Aug 1;369(5):438–47.
6. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone with Lenalidomide extension in patients with Smoldering or Newly Diagnosed Multiple Myeloma. *JAMA Oncol*. 2015 Sep;1(6):746–54.
7. Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, et al. The changing landscape of Smoldering Multiple Myeloma: a European perspective. *The Oncologist*. 2016 Mar;21(3):333–42.
8. Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. *Blood*. 2014 Nov 27;124(23):3380–8.
9. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. *Blood*. 2015 May

14;125(20):3069–75.

10. Kumar SK. Timing of treatment of smoldering myeloma: delay until progression. *Blood Adv.* 2018 Nov 13;2(21):3050–3.
11. Castaneda-Avila MA, Ulbricht CM, Epstein MM. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. *Ann Hematol.* 2021 Apr;100(4):855–63.
12. Chang SH, Luo S, Thomas TS, O'Brian KK, Colditz GA, Carlsson NP, et al. Obesity and the transformation of monoclonal gammopathy of undetermined significance of multiple myeloma: a population-based cohort study. *J Natl Cancer Inst [Internet].* 2017 May 1 [cited 2020 Apr 20];109(5). Available from: <https://academic.oup.com/jnci/article/109/5/djw264/2758640>
13. Kleinstern G, Larson DR, Allmer C, Norman AD, Muntifering G, Sinnwell J, et al. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. *Blood Cancer J.* 2022 Apr 19;12(4):67.
14. Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, et al. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. *Blood Adv.* 2017 Nov 14;1(24):2186–92.
15. Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel AV, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. *CA Cancer J Clin.* 2020 Jul;70(4):245–71.
16. Patterson RE, Laughlin GA, LaCroix AZ, Hartman SJ, Natarajan L, Senger CM, et al. Intermittent fasting and human metabolic health. *J Acad Nutr Diet.* 2015 Aug;115(8):1203–12.
17. Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet. *Nutr J.* 2004 Oct 20;3:19.
18. Tsofliou F, Vlachos D, Hughes C, Appleton KM. Barriers and facilitators associated with the adoption of and adherence to a Mediterranean style diet in adults: a systematic review of published observational and qualitative studies. *Nutrients.* 2022 Oct 15;14(20):4314.
19. Clifton KK, Ma CX, Fontana L, Peterson LL. Intermittent fasting in the prevention and treatment of cancer. *CA Cancer J Clin.* 2021 Nov;71(6):527–46.

20. Liu D, Huang Y, Huang C, Yang S, Wei X, Zhang P, et al. Calorie restriction with or without time-restricted eating in weight loss. *N Engl J Med*. 2022 Apr 21;386(16):1495–504.
21. Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. *Trends Cancer*. 2019 Aug;5(8):475–94.
22. Hatori M, Vollmers C, Zarrinpar A, DiTacchio L, Bushong EA, Gill S, et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. *Cell Metab*. 2012 Jun 6;15(6):848–60.
23. Termannsen AD, Varming A, van Elst C, Bjerre N, Nørgaard O, Hempler NF, et al. Feasibility of time-restricted eating in individuals with overweight, obesity, prediabetes, or type 2 diabetes: a systematic scoping review. *Obes Silver Spring Md*. 2023 Jun;31(6):1463–85.
24. Marinac CR, Natarajan L, Sears DD, Gallo LC, Hartman SJ, Arredondo E, et al. Prolonged nightly fasting and breast cancer risk: findings from NHANES (2009-2010). *Cancer Epidemiol Biomarkers Prev*. 2015 May;24(5):783–9.
25. Marinac CR, Nelson SH, Breen CI, Hartman SJ, Natarajan L, Pierce JP, et al. Prolonged nightly fasting and breast cancer prognosis. *JAMA Oncol*. 2016 Aug 1;2(8):1049–55.
26. Marinac CR, Sears DD, Natarajan L, Gallo LC, Breen CI, Patterson RE. Frequency and circadian timing of eating may influence biomarkers of inflammation and insulin resistance associated with breast cancer risk. *PLoS One*. 2015;10(8):e0136240.
27. Kogevinas M, Espinosa A, Castelló A, Gómez-Acebo I, Guevara M, Martin V, et al. Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study). *Int J Cancer*. 2018 Nov 15;143(10):2380–9.
28. Wang JB, Patterson RE, Ang A, Emond JA, Shetty N, Arab L. Timing of energy intake during the day is associated with the risk of obesity in adults. *J Hum Nutr Diet Off J Br Diet Assoc*. 2014 Apr;27 Suppl 2:255–62.
29. Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. *Cell Metab*. 2020 Jan 7;31(1):92-104.e5.

30. Gill S, Panda S. A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits. *Cell Metab*. 2015 Nov 3;22(5):789–98.
31. Bandura A. *Social Foundations of Thought and Action: A Social Cognitive Theory*. Englewood Cliffs, NJ: Prentice Hall; 1986.
32. Carver CS, Scheier MF. Control theory: a useful conceptual framework for personality-social, clinical, and health psychology. *Psychol Bull*. 1982 Jul;92(1):111–35.
33. Patrick K, Marshall SJ, Davila EP, Kolodziejczyk JK, Fowler JH, Calfas KJ, et al. Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART). *Contemp Clin Trials*. 2014 Jan;37(1):10–8.
34. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM. Meta-analysis: the effect of dietary counseling for weight loss. *Ann Intern Med*. 2007 Jul 3;147(1):41–50.
35. Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. *J Gen Intern Med*. 2009 Sep;24(9):1073–9.
36. Marinac CR, Birmann BM, Lee IM, Rosner BA, Townsend MK, Giovannucci E, et al. Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. *Br J Cancer*. 2018 Apr;118(7):1013–9.
37. Shah UA, Whiting K, Devlin S, Ershler R, Kanapuru B, Lee DJ, et al. Extreme body mass index and survival in newly diagnosed multiple myeloma patients. *Blood Cancer J*. 2023 Jan 12;13(1):13.
38. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med*. 2010 Dec 2;363(23):2211–9.
39. Prentice AM, Jebb SA. Beyond body mass index. *Obes Rev Off J Int Assoc Study Obes*. 2001 Aug;2(3):141–7.
40. Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM. Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. *Obes Rev Off J Int Assoc Study Obes*. 2016 Mar;17(3):262–75.

41. Zhang M, Hu T, Zhang S, Zhou L. Associations of different adipose tissue depots with insulin resistance: a systematic review and meta-analysis of observational studies. *Sci Rep*. 2015 Dec 21;5(1):18495.
42. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. *Nature*. 2006 Dec 14;444(7121):881–7.
43. De Larochellière E, Côté J, Gilbert G, Bibeau K, Ross MK, Dion-Roy V, et al. Visceral/epicardial adiposity in nonobese and apparently healthy young adults: association with the cardiometabolic profile. *Atherosclerosis*. 2014 May;234(1):23–9.
44. Falank C, Fairfield H, Reagan MR. Signaling Interplay between bone marrow adipose tissue and multiple myeloma cells. *Front Endocrinol*. 2016;7:67.
45. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. *Am J Hematol*. 2012 May;87(5):455–60.
46. Ross DM, To LB, Horvath N. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. *Intern Med J*. 2004;34(9–10):576–8.
47. Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PFH, te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. *Br J Haematol*. 2004 Apr;125(2):162–6.
48. Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. *Cancer*. 2011 Aug 15;117(16):3758–62.
49. Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: future uses for cancer prevention. *Future Oncol Lond Engl*. 2008 Feb;4(1):93–102.
50. Beger RD. A review of applications of metabolomics in cancer. *Metabolites*. 2013 Jul

5;3(3):552–74.

51. Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. *Protein Cell*. 2018 Feb;9(2):216–37.
52. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell*. 2008 Sep 5;134(5):703–7.
53. Doerstling SS, O’Flanagan CH, Hursting SD. Obesity and cancer metabolism: a perspective on interacting tumor-intrinsic and extrinsic factors. *Front Oncol*. 2017;7:216.
54. Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, Allwood JW, et al. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. *Blood Cancer J*. 2015 Oct 16;5(10):e359.
55. Piszcz J, Lemancewicz D, Dudzik D, Ciborowski M. Differences and similarities between LC-MS derived serum fingerprints of patients with B-cell malignancies. *Electrophoresis*. 2013 Oct;34(19):2857–64.
56. Kuliszkievicz-Janus M, Baczyński S. Chemotherapy-associated changes in ³¹P MRS spectra of sera from patients with multiple myeloma. *NMR Biomed*. 1995 May;8(3):127–32.
57. Lodi A, Tiziani S, Khanim FL, Günther UL, Viant MR, Morgan GJ, et al. Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. *PloS One*. 2013;8(2):e56422.
58. Puchades-Carrasco L, Lecumberri R, Martínez-López J, Lahuerta JJ, Mateos MV, Prósper F, et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2013 Sep 1;19(17):4770–9.
59. Steiner N, Müller U, Hajek R, Sevcikova S, Borjan B, Jöhrer K, et al. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. *PloS One*. 2018;13(8):e0202045.
60. Rattray NJW, Deziel NC, Wallach JD, Khan SA, Vasiliou V, Ioannidis JPA, et al. Beyond

- genomics: understanding exposotypes through metabolomics. *Hum Genomics*. 2018 Jan 26;12(1):4.
61. Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, et al. Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. *Blood Cancer J*. 2019 Jan 21;9(2):9.
62. Hildebrandt MAT, Callender RA, Belachew AA, Classen C, Lee HC, Patel KK, et al. Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies. *J Clin Oncol*. 2018 May 20;36(15_suppl):8049–8049.
63. Shim J, Hamilton DF. Comparative responsiveness of the PROMIS-10 Global Health and EQ-5D questionnaires in patients undergoing total knee arthroplasty. *Bone Jt J*. 2019 Jul;101-B(7):832–7.
64. Wilford J, Osann K, Hsieh S, Monk B, Nelson E, Wenzel L. Validation of PROMIS emotional distress short form scales for cervical cancer. *Gynecol Oncol*. 2018 Oct;151(1):111–6.
65. Schalet BD, Pilkonis PA, Yu L, Dodds N, Johnston KL, Yount S, et al. Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples. *J Clin Epidemiol*. 2016 May;73:119–27.
66. Hoos T, Espinoza N, Marshall S, Arredondo EM. Validity of the Global Physical Activity Questionnaire (GPAQ) in adult Latinas. *J Phys Act Health*. 2012 Jul;9(5):698–705.
67. Armstrong T, Bull F. Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ). *J Public Health*. 2006 Apr 1;14(2):66–70.
68. Bull FC, Maslin TS, Armstrong T. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. *J Phys Act Health*. 2009 Nov;6(6):790–804.
69. Kenfield SA, Wei EK, Rosner BA, Glynn RJ, Stampfer MJ, Colditz GA. Burden of smoking on cause-specific mortality: application to the Nurses' Health Study. *Tob Control*. 2010 Jun;19(3):248–54.
70. Cao Y, Willett WC, Rimm EB, Stampfer MJ, Giovannucci EL. Light to moderate intake of alcohol, drinking patterns, and risk of cancer: results from two prospective US cohort studies. *BMJ*.

2015 Aug 18;351:h4238.

71. Patient Reported Outcomes Measurement Information System (PROMIS) [Internet]. [cited 2023 Jan 11]. Available from: <https://www.healthmeasures.net/explore-measurement-systems/promis>
72. Mitchell JA, Quante M, Godbole S, James P, Hipp JA, Marinac CR, et al. Variation in actigraphy-estimated rest-activity patterns by demographic factors. *Chronobiol Int*. 2017;34(8):1042–56.
73. Quante M, Mariani S, Weng J, Marinac CR, Kaplan ER, Rueschman M, et al. Zeitgebers and their association with rest-activity patterns. *Chronobiol Int*. 2019 Feb;36(2):203–13.
74. Cespedes Feliciano EM, Quante M, Weng J, Mitchell JA, James P, Marinac CR, et al. Actigraphy-derived daily rest-activity patterns and body mass index in community-dwelling adults. *Sleep*. 2017 Dec 1;40(12):zxx168.
75. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer—viewpoint of the IARC Working Group. *N Engl J Med*. 2016 Aug 25;375(8):794–8.
76. Carson KR, Bates ML, Tomasson MH. The skinny on obesity and plasma cell myeloma: a review of the literature. *Bone Marrow Transplant*. 2014 Aug;49(8):1009–15.
77. van Kruijsdijk RCM, van der Wall E, Visseren FLJ. Obesity and cancer: the role of dysfunctional adipose tissue. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2009 Oct;18(10):2569–78.
78. Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: a review. *World J Diabetes*. 2010 Jul 15;1(3):76–88.
79. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF, et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. *Leukemia*. 2010 Nov;24(11):1940–50.
80. Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, et al. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. *Eur J Haematol*. 2009 Nov;83(5):460–70.
81. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Löffler D, Koczan D, et al. Interleukin-

- 6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. *Blood*. 2004 Jan 1;103(1):242–51.
82. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. *Carcinogenesis*. 2009 Jul;30(7):1073–81.
83. Hutchison AT, Heilbronn LK. Metabolic impacts of altering meal frequency and timing - Does when we eat matter? *Biochimie*. 2016 May;124:187–97.
84. Mattson MP, Allison DB, Fontana L, Harvie M, Longo VD, Malaisse WJ, et al. Meal frequency and timing in health and disease. *Proc Natl Acad Sci U S A*. 2014 Nov 25;111(47):16647–53.
85. Zhou L, Zhang Z, Nice E, Huang C, Zhang W, Tang Y. Circadian rhythms and cancers: the intrinsic links and therapeutic potentials. *J Hematol Oncol J Hematol Oncol*. 2022 Mar 4;15(1):21.
86. Mayeuf-Louchart A, Zecchin M, Staels B, Duez H. Circadian control of metabolism and pathological consequences of clock perturbations. *Biochimie*. 2017 Dec;143:42–50.
87. Chaix A, Zarrinpar A, Miu P, Panda S. Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. *Cell Metab*. 2014 Dec 2;20(6):991–1005.
88. Das M, Ellies LG, Kumar D, Saucedo C, Oberg A, Gross E, et al. Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models. *Nat Commun*. 2021 Jan 25;12(1):565.
89. Yan L, Sundaram S, Mehus AA, Picklo MJ. Time-restricted feeding attenuates high-fat diet-enhanced spontaneous metastasis of Lewis Lung Carcinoma in mice. *Anticancer Res*. 2019 Apr;39(4):1739–48.
90. Sundaram S, Yan L. Time-restricted feeding mitigates high-fat diet-enhanced mammary tumorigenesis in MMTV-PyMT mice. *Nutr Res N Y N*. 2018 Nov;59:72–9.
91. Jean-Baptiste M, Gries KS, Lenderking WR, Fastenau J. Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective. *J Patient-Rep*

Outcomes. 2020 Nov 9;4(1):95.

92. Lomas OC, Mouhieddine TH, Tahri S, Ghobrial IM. Monoclonal Gammopathy of Undetermined Significance (MGUS)—not so asymptomatic after all. *Cancers* [Internet]. 2020 Jun 12 [cited 2021 Jun 12];12(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352603/>
93. Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA. Fasting: the history, pathophysiology and complications. *West J Med*. 1982 Nov;137(5):379–99.
94. International Food Information Council. 2023 Food and Health Survey [Internet]. 2023. Available from: 23 May 2023

Table 1. Study Eligibility Criteria

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none">• Age, ≥ 18 years• BMI, ≥ 25 kg/m²• Diagnosis of MGUS, SMM, or SWM• Currently fasting for <14 hrs/night, as assessed by 24-hr food recalls• Owns cellular phone; comfortable with sending and receiving text messages• Ability to understand and willing to sign a written informed consent document	<ul style="list-style-type: none">• Diagnosis of overt MM• Diagnosis of another malignancy requiring active therapy• Diagnosis of diabetes mellitus, unless consent from patient's physician managing participant's clinical care.• Any medical or lifestyle condition contraindicated in or would interfere with study intervention (e.g., night eating syndrome, night shift work)• Currently taking medications intended for weight loss or participating in other weight loss program

Abbreviations: MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; SMM, smoldering multiple myeloma; SWM, Smoldering Waldenström macroglobulinemia

Figure 1: Schematic of study design. Timeline of participant recruitment, baseline visit, randomization to intervention or control arm, and end-of-study visit, with assessments that include tumor biomarkers, body composition, 24-hour food recalls, quality-of-life and lifestyle survey, and ActiGraph.




Figure 2: Example text message interaction with study participant. Example of an interaction in which a participant in the intervention arm submits texts to indicate the beginning and end of overnight fast and, in turn, is provided with automated, encouraging messages promoting cumulative adherence and achievement of fasting goal.

Time Stamp	Message Status	Message Content
2/17/13, 6:00PM	Sent	Remember: Calories break a fast! Once you start, you need be calorie-free 😊
2/17/13, 7:28PM	Received	FAST
2/17/13, 7:29PM	Response	Thanks! You are now running calorie free! Check back in the morning for your end time.
2/18/13, 7:00AM	Sent	Your fast ends at 9.28am. You can do it!
2/18/13, 9:55AM	Received	EAT
2/18/13, 10:05AM	Response	Congratulations! Your success rate is 100%. Nice work!